Concepedia
Statistics
Publications
7
Citations
259
H-Index
Active since
1998
Affiliations
Bayer (United States)(Current)
Memorial Sloan Kettering Cancer Center
Hopp Children's Cancer Center Heidelberg
The University of Texas MD Anderson Cancer Center
Institut Curie
Esther De La Cuesta is an author at Bayer (United States) specializing in oncology, medicine, and pharmacology.
Publications per year
1998–2025
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
François Doz, Cornelis M. van Tilburg, Birgit Geoerger et al. · Neuro-Oncology · 2021 · 170 citations · Full text
Medicine, Oncology, Pharmacology +17
A newborn with a large <i>NTRK</i> fusion positive infantile fibrosarcoma successfully treated with larotrectinib
Kenneth J. Caldwell, Esther De La Cuesta, Cara E. Morin et al. · Pediatric Blood & Cancer · 2020 · 21 citations
1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Ray McDermott, Cornelis M. van Tilburg, Anna F. Farago et al. · Annals of Oncology · 2020 · 17 citations
Medicine, Oncology, Pharmacology +16
Discovery of a rare <i>GKAP1-NTRK2</i> fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
Lily Deland, Simon Keane, Thomas Olsson Bontell et al. · Cancer Biology & Therapy · 2021 · 15 citations · Full text
Medicine, Genetics, Oncology +17
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert et al. · Journal of Clinical Oncology · 2025 · 13 citations · Full text
1–5 of 7